Fig. 4.

Off-treatment outcomes according to pretreatment HBV DNA levels stratified by end-of-treatment HBsAg levels.

Cumulative probability of clinical relapse and HBsAg loss according to pretreatment HBV DNA levels for patients with end-of-treatment HBsAg levels above (n = 557; 95 [17.1%] with pretreatment HBV DNA <20,000 IU/ml) or below 100 IU/ml (n = 200; 55 [27.5%] with pretreatment HBV DNA <20,000 IU/ml). A pretreatment HBV DNA level <20,000 IU/ml was associated with a lower cumulative risk of clinical relapse (p = 0.001 by log-rank test) and a higher cumulative chance of HBsAg loss (p <0.001 by log-rank test) among patients with HBsAg >100 IU/ml at the end of treatment; similar results were obtained among patients with HBsAg <100 IU/ml at the end of treatment (p <0.001 for clinical relapse and p <0.001 for HBsAg loss).